Corporate
News release
TopTerumo India, the Indian arm of Terumo Corporation (TSE: 4543), a global leader in medical technology, recently announced the launch of Occlusafe™ and LifePearl™, intended for use in the management of Liver Cancer.
Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer with more than 20,000 cases getting added every year in India. HCC can be treated with management approaches ranging from surgical resection to minimally invasive options.
Embolization is one such minimally invasive management option. In this, the blood supply to the tumour is blocked. This deprives the tumour of nutrients and oxygen, which induces death of these tumour cells. The most common type of Embolization is Transcatheter Arterial Chemo-Embolization (TACE), a clinical-guideline recommended, minimally invasive management option for intermediate stage liver cancer.
For the first time in India, Japan based company, Terumo, has introduced an advanced therapy called Balloon-TACE (B-TACE) for the management of liver cancer. With Occlusafe™, Terumo’s B-TACE device, patients benefit from more precise & targeted delivery of chemotherapy drug to the tumour. Additionally, damage to surrounding healthy tissues is minimised. This is associated with improved response rates with significantly fewer repeat treatments required versus TACE alone. This offers the potential to preserve liver function.
Another value addition to be introduced in the area of liver cancer care is LifePearl™. LifePearl™ helps release chemotherapeutic drug in a controlled and sustained manner at the targeted tumour site inside the liver.
Occlusafe™ and LifePearl™ are known to improve clinical outcomes for liver cancer patients treated with TACE.
Elaborating on the therapy, Shishir Agarwal, MD, Terumo India, said, “At Terumo, our mission is to contribute to society through healthcare. We aim to bring the latest Japanese medical technologies to India to advance the quality of care for patients and physicians. Occlusafe™ and LifepearlTM will offer alternate management options to support liver cancer care in India.”
Terumo India aims to expand interventional oncology portfolio with novel therapeutic solutions, and to provide a more comprehensive toolkit for managing cancer care. It’s commitment to advancing healthcare in India is built on the foundation of research and cutting-edge technology through a profound understanding of the healthcare system.
Terumo India is part of Terumo Corporation, a global leader in medical technology with headquarters in Tokyo, Japan. With 100 years of experience, Terumo’s extensive medical device portfolio ranges from vascular intervention, cardio-surgical solutions, blood transfusion, and cell therapy technology to medical products essential for daily clinical practice.
Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer with more than 20,000 cases getting added every year in India. HCC can be treated with management approaches ranging from surgical resection to minimally invasive options.
Embolization is one such minimally invasive management option. In this, the blood supply to the tumour is blocked. This deprives the tumour of nutrients and oxygen, which induces death of these tumour cells. The most common type of Embolization is Transcatheter Arterial Chemo-Embolization (TACE), a clinical-guideline recommended, minimally invasive management option for intermediate stage liver cancer.
For the first time in India, Japan based company, Terumo, has introduced an advanced therapy called Balloon-TACE (B-TACE) for the management of liver cancer. With Occlusafe™, Terumo’s B-TACE device, patients benefit from more precise & targeted delivery of chemotherapy drug to the tumour. Additionally, damage to surrounding healthy tissues is minimised. This is associated with improved response rates with significantly fewer repeat treatments required versus TACE alone. This offers the potential to preserve liver function.
Another value addition to be introduced in the area of liver cancer care is LifePearl™. LifePearl™ helps release chemotherapeutic drug in a controlled and sustained manner at the targeted tumour site inside the liver.
Occlusafe™ and LifePearl™ are known to improve clinical outcomes for liver cancer patients treated with TACE.
Elaborating on the therapy, Shishir Agarwal, MD, Terumo India, said, “At Terumo, our mission is to contribute to society through healthcare. We aim to bring the latest Japanese medical technologies to India to advance the quality of care for patients and physicians. Occlusafe™ and LifepearlTM will offer alternate management options to support liver cancer care in India.”
Terumo India aims to expand interventional oncology portfolio with novel therapeutic solutions, and to provide a more comprehensive toolkit for managing cancer care. It’s commitment to advancing healthcare in India is built on the foundation of research and cutting-edge technology through a profound understanding of the healthcare system.
Terumo India is part of Terumo Corporation, a global leader in medical technology with headquarters in Tokyo, Japan. With 100 years of experience, Terumo’s extensive medical device portfolio ranges from vascular intervention, cardio-surgical solutions, blood transfusion, and cell therapy technology to medical products essential for daily clinical practice.
About Terumo
Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 30,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.